Entrada Therapeutics Inc (TRDA) - Total Liabilities
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has total liabilities worth $72.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Entrada Therapeutics Inc to track the company's year-over-year net asset growth rate.
Entrada Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See TRDA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Entrada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Entrada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
China | CN¥513.57 Million |
|
Alvopetro Energy
V:ALV
|
Canada | CA$44.74 Million |
|
Kalyani Investment Company Limited
NSE:KICL
|
India | Rs10.43 Billion |
|
Oxley Bridge Acquisition Limited Class A Ordinary Shares
NASDAQ:OBA
|
USA | $12.19 Million |
|
BGF Retail Co Ltd
KO:027410
|
Korea | ₩375.06 Billion |
|
TigerElec Co. Ltd
KQ:219130
|
Korea | ₩31.40 Billion |
|
Kalekim Kimyevi Maddeler Sanayi & Ticaret AS
IS:KLKIM
|
Turkey | TL2.74 Billion |
|
AzureWave Technologies Inc
TW:3694
|
Taiwan | NT$4.26 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Entrada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Entrada Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entrada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Entrada Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $97.64 Million | -56.95% |
| 2023-12-31 | $226.83 Million | +474.23% |
| 2022-12-31 | $39.50 Million | +455.19% |
| 2021-12-31 | $7.12 Million | -91.63% |
| 2020-12-31 | $85.02 Million | +151.86% |
| 2019-12-31 | $33.76 Million | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more